Select a medication above to begin.
Camrelizumab
camrelizumab
Adult Dosing .
Dosage forms: INJ
Investigational New Drug (IND)
- [pending FDA approval]
hepatocellular CA, unresectable
- [indication/patient population pending FDA approval]
- Info: binds to PD-1 receptor on T-cells, blocking PD-1 pathway-mediated inhibition of anti-tumor immune response, resulting in decreased tumor growth
Peds Dosing .
- Dosage forms: --
Investigational New Drug (IND)
- [pending FDA approval]
- Info: not anticipated to be applicable to Peds population